U.S. Markets open in 3 hrs 29 mins

AstraZeneca PLC (AZN)

New York Stock Exchange Consolidated Issue - New York Stock Exchange Consolidated Issue Delayed Price. Currency in USD
Add to watchlist
29.14+0.07 (+0.24%)
At close: 4:03PM EDT

29.47 +0.34 (1.17%)
Pre-Market: 5:51AM EDT

People also watch
GSKNVSSNYLLYBMY
  • T
    Taylor
    Taylor
    Things seem to be getting overextended for AZN. I started receiving notifications from awe-some*sto-cks the other week and so far they have presented interesting new trade ideas.
  • V
    Victoria
    Victoria
    Do you think this thing is done selling? Showing us a buy signal now on AZN? Im not sure about you guys but awe-some*sto-ck*s has provided me with some pretty good trade ideas. I messed up executing some of them but thats on me.
  • R
    Rigvze
    Rigvze
    Fundamental growth and profitability are looking good. Higher rating at stockFA. Expected to pick up momentum.
  • Y
    YouBetcha
    YouBetcha
    Any thoughts regarding Benralizumab and approval and whether or not it will bring the share price up?
  • A
    Al on CC
    Al on CC
    What happened to Dividend? It was 1.90 a few days ago. Now .90. This site is very inaccurate.
  • J
    Joseph
    Joseph

    I think that the following news are interesting
    Food and Drug Administration (FDA) had agreed to speed up the process needed for its new lung cancer drug Imfinzi: http://www.proactiveinvestors.co.uk/companies/news/181726/astrazeneca-bolstered-by-fda-news-on-lung-cancer-drug-imfinzi-181726.html
    Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial: http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)31585-4/fulltext
    Although neither of them will mean definite FDA approval they look promising.

    AstraZeneca bolstered by FDA news on lung cancer drug Imfinzi
    AstraZeneca (LON:AZN) - The regulator has granted breakthrough therapy designation for Imfinzi
    www.proactiveinvestors.co.uk
  • M
    Mike
    Mike

    https://seekingalpha.com/article/4100024-astrazeneca-time-expand-operation

    AstraZeneca, Time To Expand The Operation
    FDA expanded label for Lynparza should help treat a wider ovarian cancer patient population. Positive phase 3 data served as the basis for the expanded approval
    seekingalpha.com
  • n
    nito
    nito
    No More Pricks – Quick Dissolvable Tablet is Set to Disrupt the Vaccine Industry
    The quest to improve vaccination efforts in developing nations may yield huge side benefits to the industrialized world; an end to needle injections.
    www.businesswire.com
  • C
    Carl
    Carl
    AZN reportedly goes ex-dividend next week. I believe the date is 8/9.
  • C
    Carl
    Carl
    Looks like $30 is the new base. Once speculation starts about who might have an interest in buying AZN, I expect the stock will move up a couple of bucks. The upcoming generous dividend makes it easy to hold and wait, especially if you bought on the recent drop.
  • C
    Carl
    Carl
    Up almost 1% in pre-market. Looks like buyers are coming back and paying up. Any speculation of a possible deal will make this baby pop, and that appears to be behind the buying interest.
  • C
    Carl
    Carl
    AZN's drop has made it more attractive as a buyout play. Next week's dividend is another positive reason to be buying in here. Just saw an article saying PFE's less than stellar earnings show a need to do a deal. If not PFE, could be another large pharma come a knockin'.
  • j
    junpeng
    junpeng
    It will go up
  • A
    Athra Jatt
    Athra Jatt
    AZN should give us a bit of a pop today.
  • H
    Hey Hey Hey
    Hey Hey Hey
    For as much as I want a buyout, I don't think it will happen with Soriot and the current board. Soriot has to go before he destroys anymore shareholder value. The media has to stop to referring to the PFE offer #$%$ GBP/share, that minimizes the damage Soriot has already inflicted on the shareholders including that homer Woodford. The PFE offer was $116-$120 Billion. Soriot cost the shareholders $45+ Billion dollars. None of the promises from his forked tongue will come to fruition. All we can hope for is if an activist shareholder can force the company to put itself up for sale.. I can't believe any of the large shareholders can just sit passively as Soriot continues to sell off the family jewels to hit his bonus.
  • J
    Joe
    Joe
    Benralizumab has an FDA action date during Q4 2017 and AstraZeneca are preparing to launch in the US in the beginning of 2018 .
  • s
    smok
    smok
    I bought some AZN because they make great meds. So thankful.
  • j
    jaroslav
    jaroslav
    up to 34
  • j
    junpeng
    junpeng
    AH traded @$31.5, was it for real?
  • H
    Hey Hey Hey
    Hey Hey Hey
    I expect Soriot to leave for Teva now that the bad news is out since he can't be accused of acting on non-public info anymore. If the board has any sense of fairness to the shareholders, this company should be put up for sale.